1.Mechanism of action

Enhanced hypoglycemic effect: Synergistically promote insulin secretion, inhibit glucagon release, and improve insulin sensitivity.

Strengthened weight loss effect: More potently suppress appetite, delay gastric emptying, and may regulate fat metabolism through the GIP receptor, further enhancing the weight loss efficiency.

2.R & D progress

Weight loss indication:

In Chinese subjects with a BMI ≥ 28, once - weekly administration (maximum dose of 9mg) for 48 weeks resulted in an average weight loss of approximately 12 - 14 kg (about 2 - 3 kg in the placebo group), and the weight loss amplitude was better than that of some single - target GLP - 1 drugs (such as liraglutide).

Metabolic indicators such as waist circumference, body fat percentage, and liver enzymes (ALT/AST) were significantly improved.

Type 2 diabetes indication:

The reduction in glycated hemoglobin (HbA1c) was approximately 1.5% - 2.0%, and fasting blood glucose and post - meal blood glucose control were better than those of the placebo.

The risk of hypoglycemia is low, and the safety of monotherapy or combination with metformin is good.

3.Dosage form and usage

Dosage form: Subcutaneous injection (prefilled pen). The currently disclosed specifications are 3mg/pen, 6mg/pen, and 9mg/pen. It is injected once a week (more convenient for use than the daily - injected liraglutide).

Recommended dosage:

The starting dose is 3mg/week, increased to 6mg every 4 weeks, and then increased to 9mg (the maximum dose) according to the tolerance.